- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03841357
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA) (Limit-JIA)
An Open Label, Multi-Center, Phase 3 Efficacy Study of Sub-Q Abatacept in Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Part I enrolled participants into a randomized open-label multicenter trial with a planned sample size of 306 JIA participants recruited from CARRA Registry sites. Participants were randomly allocated (1:1) to receive 24 weeks of abatacept plus usual care or usual care alone. Upon completion of 24 weeks of randomized treatment, each participant was to receive usual care and undergo follow-up for assessment of outcomes for an additional 12 months. Planned duration of the study for each participant was 18 months. Due to slow accrual and apparent loss of equipoise, enrollment into Part I has been discontinued 17February2022 As of October 29, 2021, 39 participants have been randomized in Part I. Part I participants will continue follow-up as planned.
Part II is a non-randomized continuation of LIMIT-JIA with planned enrollment of 89 to reach 80 evaluable participants receiving to the abatacept arm. Participants will now receive 24 doses of abatacept plus usual care. Upon completion of 24 doses of treatment, each participant will receive usual care and undergo follow-up for assessment of outcomes for an additional 6 months. Planned duration of the study for each participant is 12 months. Part II will assess the efficacy of abatacept in prevention of disease extension by comparison of outcomes between participants enrolled in the abatacept arm and 428 CARRA Registry patients who would have met major eligibility criteria for LIMIT-JIA.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Alex Fist, MPH
- Phone Number: 919-660-8136
- Email: alex.fist@duke.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California at San Francisco Medical Center
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- The Children's Hospital Colorado
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Shands at the University of Florida
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Riley Hospital for Children at Indiana University Health
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals of Clinics
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville School of Medicine/ Norton Charities Pediatric Clinical Research Unit
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55454
- University of Minnesota; Children's Hospital and Clinics of Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
-
New York
-
Bronx, New York, United States, 10461
- Children's Hospital at Montefiore/ Albert Einstein University Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- University of North Carolina
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, United States, 44109
- MetroHealth System
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Monroe Carell Jr Children's Hospital at Vanderbilt
-
-
Utah
-
Salt Lake City, Utah, United States, 84158
- University of Utah
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
To be eligible for this trial, participants must meet all of the following criteria in order to be include in the study:
- Age ≥ 2 years old and ≤16.5 years old
- Clinical diagnosis of JIA by a pediatric rheumatologist within the past 6 months
- Arthritis affecting ≤4 joints between disease onset and enrollment
- Enrollment in the CARRA Registry
- Participants of childbearing potential must agree to remain abstinent or agree to use an effective and medically acceptable form of birth control from the time of written or verbal assent to at least 66 days after taking the last dose of study drug.
- Weight ≥50 kg (Canadian Sites only) ¹ Enrollment is defined as having signed consent to participate in the Limit-JIA study.
The presence of any of the following will exclude a study participant from inclusion in the study:
- 1. Systemic JIA as defined by 2004 ILAR criteria1
- Sacroiliitis (clinical or radiographic)
- Inflammatory bowel disease (IBD)
- History of psoriasis or currently active psoriasis
- History of uveitis or currently active uveitis
- Prior treatment with systemic medication(s) for JIA (e.g. one or more of the following: DMARD or biologic medication)
- Current or previous (within 30 days of enrollment) treatment with systemic glucocorticoids (A short course of oral prednisone [≤ 14 days] is allowed)
- History of active or chronic liver disease
- Chronic or acute renal disorder
- AST (SGOT), ALT (SGPT) or BUN >2 x ULN (upper limit of normal) or creatinine >1.5 mg/dL or any other laboratory abnormality considered by the examining physician to be clinically significant within 2 months of the enrollment visit
- Presence of any medical or psychological condition or laboratory result which would make the participant, in the opinion of the investigator, unsuitable for the study
- Participation in another concurrent clinical interventional study within 30 days of enrollment
- Known positive human immunodeficiency virus (HIV)
- Received a live virus vaccine within 1 month of the baseline visit
- Current or prior positive Purified Protein Derivative (PPD) test or Quantiferon Gold TB
- Pregnant, breast feeding, or planned breast feeding during the study duration
- Planned transfer to non-participating pediatric rheumatology center or adult rheumatologist in the next 12 months
- Active malignancy of any type or history of malignancy
- Chronic or active infection or any major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 30 days or oral antibiotics within 14 days prior to screening
- Primary language other than English or Spanish
- Positive for Hepatitis B surface antigen or core antibody
- <10 Kg in weight
- If a potential subject has symptoms consistent with COVID-19 and/or known COVID-19 exposure at screening, it is recommended that the site follow CDC guidance regarding testing and quarantine requirements. The subject can be re-screened when there is no longer concern for active infection. A subject with a positive COVID -19 test may be re-screened.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Abatacept and Usual Care (Part I)
Weekly abatacept injection at standard dosing for weight plus usual care with steroid joint injection and non-steroidal anti-inflammatory drugs per the discretion of the treating provider
|
Supplied as a weekly injection via a pre-filled syringe
Other Names:
Usual care will be defined by the clinical management team but includes steroid joint injections and non- steroidal anti-inflammatory drugs
|
Active Comparator: Active Comparator: Usual Care (Part I)
Usual care includes steroid joint injections and treatment with non-steroidal anti-inflammatory drugs at the discretion of the treating provider
|
Usual care will be defined by the clinical management team but includes steroid joint injections and non- steroidal anti-inflammatory drugs
|
Experimental: Abatacept and Usual Care (Part II)
Weekly abatacept injection at standard dosing for weight plus usual care with steroid joint injection and non-steroidal anti-inflammatory drugs per the discretion of the treating provider
|
Supplied as a weekly injection via a pre-filled syringe
Other Names:
Usual care will be defined by the clinical management team but includes steroid joint injections and non- steroidal anti-inflammatory drugs
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Joint Count by Physician Exam (Part I)
Time Frame: Baseline, up to 18 months
|
The number of affected joints involved at protocol specified visits by physician exam.
|
Baseline, up to 18 months
|
Change in Joint Count by Physician Exam (Part II)
Time Frame: Baseline, up to 12 months
|
The number of affected joints involved at protocol specified visits by physician exam.
|
Baseline, up to 12 months
|
Change in Number of participants with active anterior uveitis (Part I)
Time Frame: Baseline, up to 18 months
|
The presence of active anterior uveitis, defined according to the Standardization of Uveitis Nomenclature for Reporting Clinical Data (SUN criteria) as the presence of one or more cells in each 1mm x 1mm slit beam field,84 will be assessed at standard of care ophthalmology visits
|
Baseline, up to 18 months
|
Change in Number of participants with active anterior uveitis (Part II)
Time Frame: Baseline, up to 12 months
|
The presence of active anterior uveitis, defined according to the Standardization of Uveitis Nomenclature for Reporting Clinical Data (SUN criteria) as the presence of one or more cells in each 1mm x 1mm slit beam field,84 will be assessed at standard of care ophthalmology visits
|
Baseline, up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in pain score as measured by PROMIS (patient reported outcome measurement system) (Part I)
Time Frame: Baseline, up to 18 months
|
We will use The Patient Reported Outcomes Measurement Information System (PROMIS), to compare patient and caregiver reported outcomes between the groups.
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centeredmeasures that evaluates and monitors physical, mental, and social health in adults and children.
|
Baseline, up to 18 months
|
Change in pain score as measured by PROMIS (patient reported outcome measurement system) (Part II)
Time Frame: Baseline, up to 12 months
|
We will use The Patient Reported Outcomes Measurement Information System (PROMIS), to compare patient and caregiver reported outcomes between the groups.
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centeredmeasures that evaluates and monitors physical, mental, and social health in adults and children.
|
Baseline, up to 12 months
|
Change in fatigue level as measured by PROMIS (Part I)
Time Frame: Baseline, up to 18 months
|
We will use The Patient Reported Outcomes Measurement Information System (PROMIS), to compare patient and caregiver reported outcomes between the groups.
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centeredmeasures that evaluates and monitors physical, mental, and social health in adults and children.
|
Baseline, up to 18 months
|
Change in fatigue level as measured by PROMIS (Part II)
Time Frame: Baseline, up to 12 months
|
We will use The Patient Reported Outcomes Measurement Information System (PROMIS), to compare patient and caregiver reported outcomes between the groups.
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centeredmeasures that evaluates and monitors physical, mental, and social health in adults and children.
|
Baseline, up to 12 months
|
Change in functional ability by PROMIS (Part I)
Time Frame: Baseline, up to 18 months
|
We will use The Patient Reported Outcomes Measurement Information System (PROMIS), to compare patient and caregiver reported outcomes between the groups.
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centeredmeasures that evaluates and monitors physical, mental, and social health in adults and children.
|
Baseline, up to 18 months
|
Change in functional ability by PROMIS (Part II)
Time Frame: Baseline, up to 12 months
|
We will use The Patient Reported Outcomes Measurement Information System (PROMIS), to compare patient and caregiver reported outcomes between the groups.
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centeredmeasures that evaluates and monitors physical, mental, and social health in adults and children.
|
Baseline, up to 12 months
|
Change in anxiety by PROMIS (Part I)
Time Frame: Baseline, up to 18 months
|
We will use The Patient Reported Outcomes Measurement Information System (PROMIS), to compare patient and caregiver reported outcomes between the groups.
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centeredmeasures that evaluates and monitors physical, mental, and social health in adults and children.
|
Baseline, up to 18 months
|
Change in anxiety by PROMIS (Part II)
Time Frame: Baseline, up to 12 months
|
We will use The Patient Reported Outcomes Measurement Information System (PROMIS), to compare patient and caregiver reported outcomes between the groups.
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centeredmeasures that evaluates and monitors physical, mental, and social health in adults and children.
|
Baseline, up to 12 months
|
Change in depression by PROMIS (Part I)
Time Frame: Baseline, up to 18 months
|
We will use The Patient Reported Outcomes Measurement Information System (PROMIS), to compare patient and caregiver reported outcomes between the groups.
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centeredmeasures that evaluates and monitors physical, mental, and social health in adults and children.
|
Baseline, up to 18 months
|
Change in depression by PROMIS (Part II)
Time Frame: Baseline, up to 12 months
|
We will use The Patient Reported Outcomes Measurement Information System (PROMIS), to compare patient and caregiver reported outcomes between the groups.
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centeredmeasures that evaluates and monitors physical, mental, and social health in adults and children.
|
Baseline, up to 12 months
|
Change in global health by PROMIS (Part I)
Time Frame: Baseline, up to 18 months
|
Global health is defined as overall well being; We will use The Patient Reported Outcomes Measurement Information System (PROMIS), to compare patient and caregiver reported outcomes between the groups.
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centeredmeasures that evaluates and monitors physical, mental, and social health in adults and children.
|
Baseline, up to 18 months
|
Change in global health by PROMIS (Part II)
Time Frame: Baseline, up to 12 months
|
Global health is defined as overall well being; We will use The Patient Reported Outcomes Measurement Information System (PROMIS), to compare patient and caregiver reported outcomes between the groups.
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centeredmeasures that evaluates and monitors physical, mental, and social health in adults and children.
|
Baseline, up to 12 months
|
Change in family impact by PedsQL (Part I)
Time Frame: Baseline, up to 18 months
|
The PedsQL (Pediatric Quality of Life InventoryTM) Measurement Model is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions.
|
Baseline, up to 18 months
|
Change in family impact by PedsQL (Part II)
Time Frame: Baseline, up to 12 months
|
The PedsQL (Pediatric Quality of Life InventoryTM) Measurement Model is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions.
|
Baseline, up to 12 months
|
Change in medications side effects by JAMAR (Part 1)
Time Frame: Baseline, up to 18 months
|
Baseline, up to 18 months
|
|
Change in medications side effects by JAMAR (Part II)
Time Frame: Baseline, up to 12 months
|
Baseline, up to 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laura Schanberg, MD, Duke University
- Principal Investigator: Eveline Wu, MD, University of North Carolina, Chapel Hill
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Juvenile
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Abatacept
Other Study ID Numbers
- Pro00100523
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Juvenile Idiopathic Arthritis
-
University of AarhusAarhus University HospitalCompletedPolyarticular Juvenile Rheumatoid Arthritis | Systemic Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis, OligoarthritisDenmark
-
Institut National de la Santé Et de la Recherche...CompletedSystemic-Onset Juvenile Idiopathic ArthritisFrance
-
GeneScience Pharmaceuticals Co., Ltd.Not yet recruitingActive Systemic Juvenile Idiopathic ArthritisChina
-
Novartis PharmaceuticalsCompletedSystemic Juvenile Idiopathic Arthritis (SJIA)Italy, Russian Federation, Turkey, Belgium, Spain, Germany, France, Israel, Canada, United States, Hungary, Austria, Brazil, Sweden, Netherlands, Poland
-
Novartis PharmaceuticalsPediatric Rheumatology International Trials OrganizationCompletedSystemic Juvenile Idiopathic Arthritis With Active FlareUnited States, Argentina, Canada, Switzerland, Germany, Israel, South Africa, Belgium, Italy, Spain, France, Brazil, Turkey, Hungary, Poland, Norway, Sweden, Netherlands, Peru
-
University of British ColumbiaUniversity of Manitoba; The Hospital for Sick Children; McGill University Health... and other collaboratorsRecruiting
-
AbbVieCompletedPolyarticular Juvenile Idiopathic Arthritis
-
NovartisCompletedArthritis, Juvenile RheumatoidItaly
-
Assistance Publique - Hôpitaux de ParisRecruitingJuvenile Idiopathic Arthritis (JIA)France
-
AbbVieRecruitingJuvenile Idiopathic Arthritis (JIA)United States, Germany, Hungary, Israel, Puerto Rico, Spain, Japan, Canada, Italy, Sweden
Clinical Trials on Abatacept Injection
-
Marmara UniversityThe Scientific and Technological Research Council of TurkeyRecruitingLRBA Deficiency | CTLA4 HaploinsufficiencyTurkey
-
St George's, University of LondonCompletedRheumatoid ArthritisUnited Kingdom
-
University of Erlangen-Nürnberg Medical SchoolUnknown
-
Johns Hopkins UniversityBristol-Myers SquibbTerminated
-
Fundacion Clinic per a la Recerca BiomédicaActive, not recruitingPalindromic Rheumatism, WristSpain
-
Bristol-Myers SquibbCompletedUlcerative ColitisUnited States, Australia, India, Korea, Republic of, Poland, Canada, France, Brazil, Mexico, Puerto Rico, Belgium, Switzerland, Italy, Netherlands, Germany, Ireland, South Africa, United Kingdom, Czech Republic
-
University Medical Center GroningenBristol-Myers SquibbCompletedSjögren's SyndromeNetherlands
-
Melbourne HealthNational Health and Medical Research Council, Australia; Juvenile Diabetes...Active, not recruitingDiabetes Mellitus, Type 1 | Type 1 DiabetesAustralia
-
Bristol-Myers SquibbCompletedRheumatoid ArthritisUnited States
-
Rüdiger B. MüllerBristol-Myers SquibbCompletedRheumatoid ArthritisSwitzerland